The Prime Study: Survival Outcomes in Patients with KRAS/NRAS Wild-Type Metastatic Colorectal Cancer and Non-Liver-Limited Disease
Jean‐Yves Douillard(European Society for Medical Oncology), R. Sidhu(McMaster University), Simona Salvatore(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya), Jan-Henrik Terwey(Amgen (Switzerland)), Reija Koukakis(Amgen (United Kingdom)), Marc Peeters(Ghent University Hospital)
Cited by 0
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k